Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson's disease. MIN-101 is a compound that blocks serotonin receptors and sigma receptors, two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-hydroxytryptamine type 1A (5-HT1A). MIN-202 is a selective orexin 2 receptor antagonist. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1) protein, for the treatment of Parkinson's disease.
Industry, Sector and Symbol:
Capitalization:- Market Cap: $302.82 million
- Outstanding Shares: 36,704,000
Average Prices:- 50 Day Moving Avg: $9.14
- 200 Day Moving Avg: $8.89
- 52 Week Range: $6.50 - $14.92
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.91
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $2.90 per share
- Price / Book: 2.83
Profitability:- EBIDTA: ($32,900,000.00)
- Return on Equity: -30.21%
- Return on Assets: -24.21%
Debt:- Debt-to-Equity Ratio: 0.02%
- Current Ratio: 6.64%
- Quick Ratio: 6.64%
Misc:- Average Volume: 304,570 shs.
- Beta: 1.73
- Short Ratio: 13.32
Frequently Asked Questions for Minerva Neurosciences (NASDAQ:NERV)
What is Minerva Neurosciences' stock symbol?
Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."
How were Minerva Neurosciences' earnings last quarter?
Minerva Neurosciences, Inc (NASDAQ:NERV) issued its quarterly earnings data on Thursday, May, 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.30) by $0.01. View Minerva Neurosciences' Earnings History.
Where is Minerva Neurosciences' stock going? Where will Minerva Neurosciences' stock price be in 2017?
2 brokers have issued 1 year target prices for Minerva Neurosciences' shares. Their predictions range from $17.00 to $20.00. On average, they expect Minerva Neurosciences' stock price to reach $18.50 in the next year. View Analyst Ratings for Minerva Neurosciences.
What are analysts saying about Minerva Neurosciences stock?
Here are some recent quotes from research analysts about Minerva Neurosciences stock:
- 1. According to Zacks Investment Research, "Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The Company's pipeline will initially target the treatment of schizophrenia, major depressive disorder (MDD), insomnia, and Parkinson's disease. Its product candidates include MIN-101, MIN-117, MIN-202 and MIN-301. Minerva Neurosciences, Inc. is based in Cambridge, MA, United States. " (5/16/2017)
- 2. Jefferies Group LLC analysts commented, "We believe NERV's two candidates MIN-101 and -202 offer upside to shares. MIN-101, designed to treat negative symptoms in schizophrenia, an unmet need, has demonstrated stat sig benefits in PIIb. MIN-202, partnered with JNJ, may offer an effective tx to insomnia with fewer side effects, and has demonstrated positive data in PIIa with stat sig improvements in key sleep parameters. We assume with Buy and $17 PT." (3/6/2017)
Who are some of Minerva Neurosciences' key competitors?
Some companies that are related to Minerva Neurosciences include Achillion Pharmaceuticals (ACHN), REGENXBIO (RGNX), Alder BioPharmaceuticals (ALDR), Otonomy (OTIC), Audentes Therapeutics (BOLD), Aurinia Pharmaceuticals (AUPH), NantKwest (NK), AnaptysBio (ANAB), CytomX Therapeutics (CTMX), Intra-Cellular Therapies (ITCI), Dynavax Technologies Corporation (DVAX), Ignyta (RXDX), Sucampo Pharmaceuticals (SCMP), Seres Therapeutics (MCRB), Progenics Pharmaceuticals (PGNX), Atara Biotherapeutics (ATRA), Geron Corporation (GERN) and BioCryst Pharmaceuticals (BCRX).
Who are Minerva Neurosciences' key executives?
Minerva Neurosciences' management team includes the folowing people:
- Marc D. Beer, Independent Chairman of the Board
- Remy Luthringer Ph.D., President, Chief Executive Officer, Director
- Geoffrey Race, Executive Vice President and Chief Financial Officer
- Joseph Reilly, Chief Operating Officer, Vice President
- Frederick Ahlholm CPA, Chief Accounting Officer, Vice President
- Mark Levine, Vice President, General Counsel, Secretary
- Francesco de Rubertis Ph.D., Independent Director
- David J. Kupfer M.D., Independent Director
- Fouzia Laghrissi-Thode M.D., Independent Director
- Michele Ollier M.D., Independent Director
How do I buy Minerva Neurosciences stock?
Shares of Minerva Neurosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Minerva Neurosciences' stock price today?
One share of Minerva Neurosciences stock can currently be purchased for approximately $8.20.
MarketBeat Community Rating for Minerva Neurosciences (NASDAQ NERV)MarketBeat's community ratings are surveys of what our community members think about Minerva Neurosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Minerva Neurosciences (NASDAQ:NERV) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $18.50 (125.61% upside) |
Analysts' Ratings History for Minerva Neurosciences (NASDAQ:NERV)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 6/1/2017 | JMP Securities | Reiterated Rating | Outperform | $17.00 -> $20.00 | Low |  |
| 3/6/2017 | Jefferies Group LLC | Initiated Coverage | Buy -> Buy | $17.00 | N/A | |
(Data available from 7/20/2015 forward)
Earnings History for Minerva Neurosciences (NASDAQ:NERV)Earnings History by Quarter for Minerva Neurosciences (NASDAQ NERV)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/4/2017 | Q1 2017 | ($0.30) | ($0.30) | | | View | Listen | |
| 3/13/2017 | Q4 2016 | ($0.25) | ($0.27) | | | View | N/A | |
| 11/3/2016 | Q316 | ($0.21) | ($0.24) | | | View | Listen | |
| 8/4/2016 | Q116 | ($0.30) | ($0.18) | | | View | Listen | |
| 5/3/2016 | Q1 | ($0.33) | ($0.29) | | | View | Listen | |
| 3/14/2016 | Q4 | ($0.31) | ($0.34) | | | View | Listen | |
| 11/5/2015 | Q315 | ($0.43) | ($0.24) | | | View | Listen | |
| 8/5/2015 | Q215 | ($0.53) | ($0.27) | | | View | N/A | |
| 3/26/2015 | Q414 | ($0.53) | ($0.40) | | | View | N/A | |
| 11/6/2014 | Q3 2014 | ($2.30) | ($1.53) | | | View | N/A | |
| 8/7/2014 | Q2 | ($0.41) | ($2.33) | | | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Minerva Neurosciences (NASDAQ:NERV)2017 EPS Consensus Estimate: ($1.60)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.30) | ($0.30) | ($0.30) |
| Q2 2017 | 1 | ($0.35) | ($0.35) | ($0.35) |
| Q3 2017 | 1 | ($0.47) | ($0.47) | ($0.47) |
| Q4 2017 | 1 | ($0.48) | ($0.48) | ($0.48) |
(Data provided by Zacks Investment Research)
Dividend History for Minerva Neurosciences (NASDAQ:NERV)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Minerva Neurosciences (NASDAQ:NERV)Insider Ownership Percentage: 21.60%
Institutional Ownership Percentage: 70.07%
Insider Trades by Quarter for Minerva Neurosciences (NASDAQ:NERV)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 3/20/2017 | Marc D Beer | Director | Buy | 50,000 | $8.12 | $406,000.00 | |
| 2/6/2017 | Geoff Race | CFO | Sell | 21,450 | $11.02 | $236,379.00 | |
| 2/6/2017 | Remy Luthringer | CEO | Sell | 34,281 | $11.02 | $377,776.62 | |
| 1/11/2017 | Joseph H Reilly | COO | Sell | 1,600 | $12.03 | $19,248.00 | |
| 1/4/2017 | Mark S Levine | SVP | Sell | 17,500 | $12.00 | $210,000.00 | |
| 12/27/2016 | Frederick W Ahlholm | SVP | Sell | 17,000 | $12.51 | $212,670.00 | |
| 8/10/2016 | Venture Associates L Index III | Major Shareholder | Sell | 1,000,000 | $10.00 | $10,000,000.00 | |
| 6/21/2016 | David Kupfer | Director | Buy | 55,635 | $10.84 | $603,083.40 | |
| 3/17/2016 | David Kupfer | Director | Buy | 181,488 | $5.51 | $999,998.88 | |
| 3/18/2015 | Care Capital Iii Llc | Major Shareholder | Sell | 1,206,700 | $5.75 | $6,938,525.00 | |
| 3/18/2015 | Rubertis Francesco De | Director | Buy | 202,634 | $4.81 | $974,669.54 | |
| 3/13/2015 | & Johnson Johnson | Major Shareholder | Buy | 607,903 | $4.81 | $2,924,013.43 | |
| 1/26/2015 | Care Capital Iii Llc | Major Shareholder | Sell | 482,112 | $5.11 | $2,463,592.32 | |
| 1/8/2015 | Care Capital Iii Llc | Major Shareholder | Sell | 531,808 | $7.38 | $3,924,743.04 | |
| 7/7/2014 | Care Capital Iii Llc | Major Shareholder | Buy | 737,500 | $6.00 | $4,425,000.00 | |
| 7/7/2014 | Michele Ollier | Director | Buy | 1,620,833 | $6.00 | $9,724,998.00 | |
| 7/1/2014 | Coelho Rogerio Vivaldi | CEO | Buy | 41,667 | $6.00 | $250,002.00 | |
| 7/1/2014 | Frederick W Ahlholm | CAO | Buy | 10,000 | $6.00 | $60,000.00 | |
| 7/1/2014 | Geoff Race | CFO | Buy | 33,333 | $6.00 | $199,998.00 | |
| 7/1/2014 | Heek G Jan Van | Director | Buy | 3,333 | $6.00 | $19,998.00 | |
| 7/1/2014 | Joseph H Reilly | Insider | Buy | 8,333 | $6.00 | $49,998.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Minerva Neurosciences (NASDAQ:NERV)
Latest Headlines for Minerva Neurosciences (NASDAQ:NERV)
| Source: |
|
| Date | Headline |
|---|
 | MINERVA NEUROSCIENCES INC
www.finanznachrichten.de - July 6 at 3:43 PM |
 | Minerva Neurosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
finance.yahoo.com - July 6 at 7:18 AM |
 | Minerva Neurosciences, Inc (NERV) Given $17.00 Average Target Price by Brokerages
www.americanbankingnews.com - June 29 at 8:52 PM |
| Minerva Neurosciences Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - June 29 at 6:06 AM |
| Minerva On Track to Initiate Phase III Schizophrenia Study
finance.yahoo.com - June 27 at 6:35 AM |
 | Minerva Announces Completion of Bridging Study to Select Improved Formulation of MIN-101 for Use in
www.nasdaq.com - June 23 at 7:18 PM |
| Minerva Announces Completion of Bridging Study to Select Improved Formulation of MIN-101 for Use in Phase 3 Trial for the Treatment of Negative Symptoms in Patients With Schizophrenia
finance.yahoo.com - June 23 at 8:22 AM |
| Minerva Neurosciences Inc (NERV) Stock Rating Reaffirmed by JMP Securities
www.americanbankingnews.com - June 1 at 7:58 PM |
 | Why Minerva Shares Are Climbing
247wallst.com - June 1 at 7:38 PM |
| Minerva Neurosciences, Inc.: Minerva Announces Amended Agreement for MIN-202 in Insomnia
www.finanznachrichten.de - May 31 at 7:09 PM |
| Minerva Announces Amended Agreement for MIN-202 in Insomnia
finance.yahoo.com - May 31 at 7:09 PM |
| Minerva Neurosciences to Present at Jefferies 2017 Healthcare Conference on June 6, 2017
finance.yahoo.com - May 30 at 6:28 PM |
| Minerva Neurosciences Inc (NERV) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - May 29 at 4:20 PM |
| Minerva Neurosciences Inc (NERV) Downgraded to Strong Sell at ValuEngine
www.americanbankingnews.com - May 29 at 3:28 PM |
| Brokerages Expect Minerva Neurosciences Inc (NERV) Will Announce Earnings of -$0.35 Per Share
www.americanbankingnews.com - May 29 at 8:24 AM |
| Minerva Neurosciences Inc (NERV) Upgraded by ValuEngine to "Hold"
www.americanbankingnews.com - May 23 at 3:08 PM |
 | A Deep Dive Into Minerva Neurosciences' Pipeline
seekingalpha.com - May 16 at 6:31 PM |
 | BRIEF-Minerva Neurosciences announces outcome of meeting with FDA
www.reuters.com - May 16 at 6:31 PM |
 | Minerva (NERV) Provides Phase III Development Strategy for MIN-101
www.zacks.com - May 16 at 6:31 PM |
| Minerva Neurosciences Inc (NERV) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - May 16 at 7:34 AM |
 | Minerva Neurosciences (NERV) Reports Outcome of End-of-Phase 2 Meeting With FDA
www.streetinsider.com - May 15 at 6:08 PM |
| Minerva Announces Outcome of End-of-Phase 2 Meeting With FDA
finance.yahoo.com - May 15 at 10:13 AM |
| Minerva Provides Update on Phase 3 Design and Development Strategy for MIN-101
finance.yahoo.com - May 15 at 10:13 AM |
| Minerva Neurosciences stock rises 7% on plans to advance schizophrenia drug to late-stage trials
finance.yahoo.com - May 15 at 10:13 AM |
| Minerva Neurosciences Inc (NERV) Releases Quarterly Earnings Results, Meets Estimates
www.americanbankingnews.com - May 8 at 5:44 PM |
| Minerva Neurosciences Inc (NERV) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 6 at 9:08 AM |
| BRIEF-Minerva Neurosciences Q1 loss per share $0.30
www.reuters.com - May 4 at 6:53 PM |
| Investor Network: Minerva Neurosciences Inc to Host Earnings Call
finance.yahoo.com - May 4 at 11:25 AM |
| Minerva Neurosciences Reports First Quarter 2017 Financial Results and Business Updates
finance.yahoo.com - May 4 at 11:25 AM |
 | Minerva Neurosciences reports 1Q loss
marketbeat.com - May 4 at 8:46 AM |
| Minerva Neurosciences (NERV) Receives Daily News Sentiment Rating of 0.31
www.americanbankingnews.com - May 3 at 11:18 PM |
| Brokerages Anticipate Minerva Neurosciences Inc (NERV) to Announce -$0.30 EPS
www.americanbankingnews.com - May 3 at 8:24 PM |
| Minerva Neurosciences (NERV) Earns News Sentiment Rating of 0.31
www.americanbankingnews.com - April 29 at 1:19 AM |
| Minerva Neurosciences to Report First Quarter 2017 Financial Results and Business Updates on May 4,
www.nasdaq.com - April 28 at 12:19 AM |
| Minerva Neurosciences to Report First Quarter 2017 Financial Results and Business Updates on May 4, 2017
finance.yahoo.com - April 27 at 9:57 AM |
| Minerva Neurosciences (NERV) Receiving Somewhat Favorable Media Coverage, Report Finds
www.americanbankingnews.com - April 24 at 9:03 PM |
| LifeSci Capital Initiates Coverage of Minerva Neurosciences
finance.yahoo.com - April 18 at 6:10 PM |
| Minerva Neurosciences (NERV) Earning Somewhat Favorable Press Coverage, AlphaOne Reports
www.americanbankingnews.com - April 15 at 2:55 PM |
| Zacks: Brokerages Anticipate Minerva Neurosciences Inc (NERV) to Announce -$0.30 EPS
www.americanbankingnews.com - April 12 at 4:09 PM |
 | Former Aegerion chief Marc Beer to launch new Boston biotech
www.bizjournals.com - April 7 at 11:26 AM |
| Minerva Neurosciences Inc (NERV) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - April 5 at 9:52 PM |
| Minerva Neurosciences Inc (NERV) Lifted to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 5 at 9:01 AM |
| Zacks Investment Research Upgrades Minerva Neurosciences Inc (NERV) to "Hold"
www.americanbankingnews.com - March 30 at 11:24 PM |
 | Minerva Neurosciences Announces Recent Exercise of Warrants by Institutional Stockholders and Open Market ... - GlobeNewswire (press release)
globenewswire.com - March 23 at 7:18 PM |
| Minerva Neurosciences (NERV) Reports Exercise of Warrants, Purchase of Common Stock by Chairman
www.streetinsider.com - March 21 at 11:40 PM |
| Minerva Neurosciences Announces Recent Exercise of Warrants by Institutional Stockholders and Open
www.nasdaq.com - March 21 at 6:40 PM |
| Minerva Neurosciences Announces Recent Exercise of Warrants by Institutional Stockholders and Open Market Purchase of Common Stock by Chairman of Its Board of Directors
finance.yahoo.com - March 21 at 6:40 PM |
| Minerva Neurosciences Inc (NERV) Director Buys $406,000.00 in Stock
www.americanbankingnews.com - March 21 at 1:25 PM |
| MINERVA NEUROSCIENCES, INC. Files SEC form 8-K, Other Events
biz.yahoo.com - March 21 at 11:34 AM |
 | Biotech Premarket Movers: Esperion, Minerva and BioCryst
www.thestreet.com - March 21 at 11:34 AM |
Minerva Neurosciences (NERV) Chart for Thursday, July, 20, 2017
